6 Best Peptides for Gastritis

What to Know Before Choosing a Peptide for Gastritis

Gastritis is inflammation of the stomach lining, and it covers a wide range. At one end is a brief, acute flare triggered by NSAIDs or stress. At the other is chronic, progressive disease that gradually damages the gastric mucosa over years, sometimes leading to atrophic changes where the stomach lining loses its normal glandular cells. That range matters when looking at peptides, because the compounds people reach for differ somewhat depending on whether the goal is calming acute inflammation, supporting mucosal repair, or addressing longer-term structural deterioration.

Every compound in this guide earned its place for one reason: people actually use it or are actively discussing using it for gastritis. That is the whole test for inclusion. Not whether a compound is FDA-approved, and not whether a large randomized controlled trial exists targeting gastritis specifically. None of these compounds are FDA-approved for gastritis, and no published human clinical trial has formally used gastritis as its primary outcome for any peptide on this list. That is the honest field-level reality, stated once here so it does not need to be repeated in every entry. Each entry then describes that compound's own evidence picture as accurately as possible. Some have human trial data for closely related GI conditions. Some have strong preclinical data. Some are used primarily in functional medicine settings with limited formal study. And at least one, Stamakort, is discussed mainly within European and specialty communities with very little Western clinical literature behind it. All of them belong in this guide because all of them are part of the real conversation people are having about this goal.

The numbers in front of each entry give the list a spine, and the order reflects how prominently each compound appears in research and documented real-world use for gastritis. That is not a ranking of one compound being better than another for you. Two people with gastritis can have completely different underlying causes, ranging from H. pylori infection to NSAID overuse to autoimmune disease, and the peptide that makes sense in one context may not be the right fit in another. The right choice is personal, and that is exactly what the app is built to help work through.

1. BPC-157: The Most Studied Peptide for Gastric Mucosal Repair

BPC-157 stands for Body Protection Compound-157. It is a 15-amino acid synthetic peptide derived from a protective protein found naturally in human gastric juice. The fact that it originates from stomach tissue is part of why it has attracted so much attention for gastric and GI conditions specifically. It is the compound people are most likely to encounter when they first start researching peptides for gut health, and for good reason.

The way BPC-157 works in the stomach comes down to several overlapping pathways. It enhances VEGF signaling, which is the cellular signal that tells the body to build new blood vessels. More blood vessels to a damaged area of the gastric mucosa means better delivery of the raw materials needed to heal. Alongside that, BPC-157 induces controlled nitric oxide release, which improves blood flow and provides a protective layer against the acid and inflammatory environment inside an inflamed stomach. It also reduces key inflammatory signaling proteins, specifically TNF-alpha and IL-6, two of the primary drivers of the mucosal damage seen in gastritis.

The evidence picture for BPC-157 is the strongest of any compound on this list, though important limits apply. In animal models of gastric ulcers and mucosal damage, BPC-157 has produced consistent protective and regenerative effects across a substantial body of studies. In human research, a phase II clinical trial completed for ulcerative colitis found no toxicity and produced encouraging early results. Toxicology studies have not identified a lethal dose. What does not yet exist is a published human clinical trial that specifically targets gastritis as its primary outcome. BPC-157 is used off-label for gastritis by functional medicine providers, and community reports from the gastritis space span a wide range. Some people report meaningful improvement in burning and cramping within weeks; others, particularly those using oral forms, report limited results. Chronic cases frequently require a longer course before effects become apparent.

As of April 2026, BPC-157 was removed from the FDA's Category 2 high-risk compounding list, which opens the door to evaluation for 503A compounding eligibility. That regulatory shift matters for access but does not constitute FDA approval for any indication. In the United States, legitimate access runs through a physician prescription and a licensed compounding pharmacy. Sources labeled as research chemicals sold for human use carry real risks of contamination, mislabeling, and unknown purity.

2. KPV: For Calming the Inflammatory Response in the Gut

KPV is a tripeptide made of just three amino acids: lysine, proline, and valine. It is the C-terminal fragment of alpha-melanocyte-stimulating hormone, a naturally occurring immune-modulating signal produced by the body. Its short structure makes it unusually resistant to degradation in the GI environment, which is one reason it is considered well-suited for gut-targeted inflammatory conditions.

Where BPC-157 is known primarily as a tissue repair compound, KPV's primary strength is anti-inflammatory. It modulates the immune response in the gut epithelium, calming the inflammatory cascades that drive mucosal damage in gastritis. There is also evidence that KPV has direct antimicrobial properties, potentially relevant for gastritis driven by H. pylori infection, the most common cause of chronic gastritis worldwide. A third mechanism is support for intestinal barrier function. KPV helps maintain tight junctions between the cells lining the gut, and tight junctions are essentially the seals between adjacent cells in the gastric and intestinal epithelium. When those seals degrade, the gut becomes more permeable, and that permeability perpetuates the inflammatory cycle.

KPV's evidence base comes from experimental research and functional medicine practice rather than large clinical trials. It is used alongside BPC-157 in many gut repair protocols, with the reasoning that the two compounds address different but complementary aspects of the problem: BPC-157 supports structural repair while KPV quiets the immune overreaction that impedes healing. That combination logic has enough traction in the functional medicine world that a commercial supplement has been formulated around it. KPV was also among the peptides the FDA was evaluating for 503A compounding list consideration as of mid-2026, reflecting growing clinical interest even in the absence of formal approval.

Reported side effects with KPV are minimal. Occasional injection site irritation is the most commonly noted issue in research settings. Like BPC-157, legitimate access in the United States requires a physician prescription through a licensed compounding pharmacy.

3. Stamakort: The Peptide Bioregulator for Gastric Tissue

Stamakort belongs to a class of compounds called peptide bioregulators, developed primarily through decades of research at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Peptide bioregulators are typically short peptides, often just two to four amino acids in length, that are claimed to have organ-specific effects by influencing gene expression in target tissues. Stamakort is the gastric-specific compound in this family, derived from gastric mucosa peptides and intended to support the function and structural integrity of stomach tissue.

The proposed mechanism is tissue-level regulation. Stamakort is thought to act directly on the cells of the gastric mucosa, influencing the expression of proteins involved in maintaining and restoring the stomach lining. It is typically taken orally in enteric-coated tablet form, a design that allows it to survive transit through stomach acid and reach the target tissue more intact. The broader peptide bioregulator system developed by the same research tradition includes organ-specific preparations for the heart, liver, kidneys, brain, and other tissues. Stamakort is the gastric entry point in that system.

The evidence here is experiential rather than clinical by the standards of Western regulatory medicine. Research from the Russian Institute supports the bioregulator class broadly, including published work on longevity and organ-specific tissue support, but peer-reviewed gastritis-specific clinical trial data in Western journals is not available as of 2026. Stamakort is discussed in European and Eastern European health communities, where peptide bioregulators have a longer history of use, and among biohackers and longevity researchers who follow the Institute's output. Its presence in this guide reflects genuine use and discussion in relevant communities, not a clinical evidence base comparable to BPC-157 or KPV. Anyone approaching Stamakort should understand that the support for its specific effects on gastritis comes from the bioregulator research tradition rather than controlled gastritis trials, and independent verification of any specific claim is appropriate.

4. Larazotide: For Leaky Gut Contributing to Gastric Inflammation

Larazotide is a synthetic peptide modeled on the natural proteins that form tight junctions between gut epithelial cells. When those tight junctions break down, substances that should stay inside the gut lumen cross into the bloodstream, triggering immune activation that feeds back into local inflammation. This process plays a role in perpetuating the cycle of mucosal damage in gastritis and related conditions. Larazotide's mechanism is to restore barrier integrity by acting as a structural analog to the natural tight-junction proteins, reducing the permeability and the downstream immune burden it creates.

Most of the formal research on Larazotide has been conducted in celiac disease, where intestinal permeability is a central feature of the pathophysiology, and some human clinical data exists in that population. For gastritis specifically, no dedicated human trials have been published. Its use in gastritis protocols is largely secondary, employed in functional medicine settings when gut permeability is identified as a contributing factor alongside primary mucosal damage. GI-MAP testing, which measures markers of gut microbiome and barrier function, is one tool practitioners use to decide whether Larazotide belongs in a given protocol.

Larazotide appeared alongside BPC-157 and KPV in the group of peptides the FDA was evaluating for 503A compounding list consideration in 2026, which reflects its growing presence in clinical integrative medicine conversations. In the gastritis community, user-reported experience positions it as a supporting compound rather than a first-line intervention. It tends to appear in combination approaches, most often when barrier dysfunction is identified as a significant part of the individual's gastritis picture.

5. TB-500: For Tissue Regeneration and Reduced Fibrotic Remodeling

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in virtually all human and animal cells. Its primary roles in tissue repair are promoting the migration of cells into damaged areas, accelerating regeneration, and reducing fibrosis, which is the formation of scar tissue that can impair normal tissue function over time. TB-500 is best known in the sports recovery and injury healing community for its effects on muscle, tendon, and connective tissue. Its relevance to gastritis is more indirect than BPC-157 or KPV, but it appears in gastritis discussions frequently enough to warrant a clear-eyed entry.

The logic for TB-500 in gastritis centers on applying its regenerative properties to the gastric mucosa. Chronic gastritis, particularly the atrophic form, involves progressive loss of gastric glandular cells, and promoting cell migration while reducing fibrotic remodeling could theoretically support recovery of more normal tissue architecture. This reasoning is extrapolated from preclinical research rather than established in human gastritis trials. Animal research on TB-500 supports regenerative effects in various tissue contexts, but no study has specifically examined gastritis outcomes. The evidence for this application is inferred from TB-500's broader tissue repair profile, not derived from gastric-specific data.

The side effect profile in preclinical research is generally favorable. Injection site reactions and occasional transient flu-like symptoms are the most commonly reported issues. Active malignancy is a contraindication given the compound's effects on cell migration and tissue growth. In community gastritis discussions, TB-500 appears more as a supporting or stacked compound than as a primary intervention, typically in protocols where broader tissue regeneration is the goal alongside more gut-specific agents.

6. Natural Peptide Extract from Kangfuxin: For Chronic Atrophic Gastritis

This entry sits in a different category from the others because it involves a natural peptide mixture rather than a single synthesized compound. Kangfuxin is a preparation derived from traditional Chinese medicine, and it contains a complex of peptides that researchers have begun to characterize more precisely. The fraction of interest has been labeled PEEPA, sometimes called P5 in research literature. It is less accessible in Western functional medicine settings, but it carries the most direct gastritis-specific mechanistic evidence of any compound in this guide.

A 2024 study published in Advanced Science investigated this peptide extract specifically in the context of chronic atrophic gastritis, the progressive form of the disease where the stomach lining loses its glandular cells over time. The research used mouse models of atrophic gastritis and, critically, patient-derived gastric organoids, which are miniature lab-grown structures created from actual patient tissue. The peptide extract was shown to activate gastric stem cells, the cells responsible for replenishing the gastric epithelium, through a mechanism involving stabilization of the EGF-EGFR complex and activation of downstream signaling pathways. In plain terms, it appeared to restart the stomach lining's own repair machinery from the stem cell level up. That is a specific, mechanistically grounded finding for a condition where most conventional treatments manage symptoms rather than restore tissue architecture.

The caveat is equally important to state plainly: no full human clinical trial has been conducted. The evidence comes from mouse models and patient-derived organoids, which is a meaningful step beyond pure cell culture experiments but still a substantial distance from a clinical study in gastritis patients. Kangfuxin preparations are available through traditional Chinese medicine practitioners in regions where that tradition is practiced. They are not available through standard US compounding channels, and Western conventional practitioners are unlikely to be familiar with the research. For anyone interested in this compound, the 2024 Advanced Science study is the primary reference point, and the gap between its organoid findings and a full human trial is real and significant.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for gastritis?

No FDA-approved peptide exists specifically for gastritis as of 2026. The compounds covered in this guide are used off-label in functional medicine settings or are available through licensed compounding pharmacies via physician prescription. BPC-157 and KPV were among the peptides being evaluated for changes to FDA compounding classifications in 2026, but those regulatory reviews are not the same as drug approval for any indication.

How do people typically access these peptides?

Legitimate access in the United States runs through a physician prescription and a licensed compounding pharmacy. Functional medicine and integrative medicine providers prescribe these compounds off-label for GI conditions. Sources that sell these peptides labeled as research chemicals for human use are operating outside FDA guidelines, and the quality and purity of those products cannot be independently verified.

Can peptides replace standard gastritis treatment?

Peptides for gastritis are typically used alongside, not instead of, addressing the underlying cause. Gastritis from H. pylori requires antibiotic eradication therapy. NSAID-induced gastritis requires stopping or reducing the offending medication. User experience in the gastritis community consistently reflects that peptides work better as part of a broader approach that includes treating the root cause and modifying diet, rather than as a standalone replacement for those foundational steps.

How long does it typically take to notice results?

Community-reported timelines vary widely depending on the compound and the severity of the condition. Some people report a noticeable shift in symptoms within days to a few weeks. Chronic cases with long-standing mucosal damage commonly take several months before meaningful improvement appears. These timelines reflect user-reported experience rather than controlled clinical data, so they describe the range of what people have observed rather than a clinically validated expectation.

Is it common to use more than one of these peptides together?

Yes, combination approaches are common in functional medicine practice for gastritis. BPC-157 and KPV are the most frequently paired compounds, with the reasoning that BPC-157 addresses structural repair while KPV reduces the immune-driven inflammation that impedes healing. Some providers add Larazotide when gut permeability is identified as a significant contributing factor. The specific combination should be guided by a qualified provider who can assess the individual's full picture.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for gastritis in one place.